AI+AR Equals Altoida ’s Alzheimer’s Detection Solution

Altoida is combining artificial intelligence, machine learning, and augmented reality to help detect Alzheimer’s disease. The Houston, TX-based company has struck a chord with venture capitalists, raising $6.3 million in a series A round. The financing was led by M Ventures, the corporate venture capital arm of the science and technology company Merck KGaA, Darmstadt, Germany, with participation from Grey Sky Venture Partners, VI Partners AG, Alpana Ventures, and FYRFLY Venture Partners. The new capital will be used to further expand Altoida's presence worldwide with an immediate focus on commercialization activities in the U.S. and Europe markets. Altoida said it offers healthcare professionals a novel way to objectively assess cognitive and everyday functions, in the most ecologically valid way, prior to the onset of symptoms. The firm’s digital biomarkers harness advances in technology to detect brain changes early in the disease process, helping to accelerate early diagnosis for better clinical outcomes. Using an iPad or a Tablet accelerometer, gyroscope and touch screen sensors, Altoida is able to detect "micro-errors" as both a prognostic and diagnostic digital biomarker. The result is that medical professionals are able to detect Alzheimer's disease in patients 62+ years old between six and ten years prior to the onset of symptoms - and before irreversible damage occurs. The company’s product analyzes visuospatial ...
Source: MDDI - Category: Medical Devices Authors: Tags: Assembly and Automation Source Type: news